SpiNTec, which may have a lower cost than the immunizations that are already on the market, is being developed at the Federal University of Minas Gerais and will have two doses
The Brazilian vaccine SpiNTec, developed by CTVacinas of the Federal University of Minas Gerais (UFMG), may be used in the annual vaccination against Covid-19. The information was released this Sunday, 1, by the Minister of Science, Technology and Innovation, landmarks bridges, during a press conference. On Saturday, 31, the National Health Surveillance Agency (Anvisa) reported that it received the request to carry out phase 1 and 2 studies by SpiNTec. The analysis will consider, according to the procedures of the Anvisa, the study proposal, the number of participants, and the safety data obtained to date in preclinical laboratory and animal studies. CTVacinas is UFMG’s biotechnology research center. During an interview, which also included the participation of university representatives, Pontes stated that the work of his portfolio is in line with that of the Ministry of Health. According to the minister, SpiNTec may be used in annual campaigns, as well as other national vaccines that will emerge.
“We will have annual vaccinations. And the fact that we have national vaccines means that they can be used in these vaccinations,” said Pontes. “The idea is that we have this vaccine participating in the national plan.” The minister also highlighted the fact that vaccines such as SpiNTec are appearing at shorter intervals, in just a few months. In the past, the minister pointed out, the development of immunization agents lasted between 5 and 10 years. At the press conference, ministry technicians and UFMG researchers clarified SpiNTec’s details. THE vaccine uses the recombinant protein strategy, which consists of identifying, within the genome of the new coronavirus, sequences with information for protein production. These sequences are introduced into bacteria which, in turn, start to produce proteins that will be used to formulate the vaccine.
As the vaccine uses recombinant protein technology, the expectation is that its final cost will be lower than that of other immunizing agents that are already on the market. From the tests already carried out, the vaccine worked in animals. Now, the researchers hope, with Anvisa’s agreement, to test it on human beings. The researchers’ expectation is that SpiNTec is applied in two doses – like most vaccines already authorized in the country – at intervals of 21 days. In pre-clinical trials, tests were carried out with at least one of the variants of the new coronavirus and the Brazilian immunizing agent proved to be effective.
*With information from Estadão Content.